



PRESS RELEASE

BMJH-SANKALP Centre for Paediatric Haematology, Oncology and Bone Marrow Transplantation Becomes India's First JACIE-Certified Centre

Barcelona, 26 August 2026 – The BMJH Sankalp Centre for Paediatric Haematology Oncology, a joint initiative by the Sankalp India Foundation and Bhagwan Mahaveer Jain Hospital to provide access to cures for serious blood disorders in children, has become the first centre in India to achieve JACIE certification, a landmark milestone for haematopoietic cell transplantation and cellular therapy in the country.

JACIE certification is a globally recognised benchmark for quality in haematopoietic cell transplantation and cellular therapy. The certification assesses all aspects of the transplant programme, including clinical care, stem cell collection, laboratory processing, and quality management systems, to ensure the delivery of safe, consistent, and effective care for patients based on FACT-JACIE Standards.

The achievement reflects the dedication of the multidisciplinary teams at BMJH-SANKALP Centre for Paediatric Haematology, Oncology and Bone Marrow Transplantation, who have worked collaboratively to embed quality and continuous improvement across the entire transplant pathway. By meeting JACIE's rigorous requirements, the centre joins an international network of transplant programmes committed to excellence in patient care.

As access to stem cell transplantation continues to expand across India, ensuring quality alongside access is essential. For children with life-threatening blood disorders, including thalassaemia and sickle cell disease, transplantation can provide a cure. Achieving JACIE certification demonstrates that world-class care can be delivered consistently while broadening access to treatment.

Dr. Mohana Reddy, Paediatric Haematologist-Oncologist and Bone Marrow Transplant Physician; Program Director, Sankalp India Foundation BMJH, Bengaluru, India, said:

"For the families we serve, this achievement represents much more than a certification. It is an assurance that their children are receiving care that meets internationally recognised standards of quality and safety. We are grateful to our teams, partners and supporters whose unwavering commitment has made this milestone possible, and we remain focused on expanding access to lifesaving therapies for children across India."



PRESS RELEASE

Dr Rajat Kumar Agarwal, President, Sankalp India Foundation, added:

"For children with thalassemia and sickle cell disease in low- and middle-income countries, access to transplant must go hand in hand with quality and safety—one cannot come without the others. This certification proves that world-class care is achievable in resource-limited settings — and we hope it inspires more centres to meet global standards of quality, not simply the volume."

Dr Charles Crawley, Chair of the JACIE Working Party congratulated the centre on its achievement:

"JACIE certification is not awarded for a single achievement, but for demonstrating consistent excellence across an entire programme over time. As the first centre in India to attain JACIE certification, BMJH-SANKALP Centre for Paediatric Haematology, Oncology and Bone Marrow Transplantation, has shown what can be accomplished through long-term commitment, collaboration and rigorous processes. We are delighted to welcome the programme into the international community of JACIE-certified centres."

About EBMT:

The EBMT is a non-profit medical and scientific organisation established in 1974 which hosts a unique patient registry providing a pool of data to perform studies and assess new trends. We aim to be the connection between patients, researchers and other stakeholders to anticipate the future of cellular and stem cell-based therapies. Our community of healthcare professionals is focused on innovation, research and the advancement of these fields to save and improve the lives of patients with blood-related disorders.

For more information, please visit www.ebmt.org.

About JACIE:

JACIE is Europe's only official certification body in the field of haematopoietic cell transplantation (HCT) and cellular therapy (CT). It promotes high-quality patient care and medical and laboratory practice through a profession-led, voluntary certification scheme.

Press Contact :

Mélanie Chaboissier

Communication Coordinator, EBMT

Email: melanie.chaboissier@ebmt.org